Abivax Navigates Efficacy Triumph and Safety Scrutiny with Strong Cash Position

Abivax holds €491.6M cash, funding operations into Q4 2027, providing flexibility amid Obefazimod safety concerns. Analysts split on stock, with targets from $90 to $187.

Abivax has plenty of financial breathing room, and that may prove crucial as the biotech group works to convince markets its blockbuster candidate Obefazimod can overcome a safety cloud. The company held €491.6 million in cash and short-term investments as of March 31, enough to fund operations into the fourth quarter of 2027, well past the key FDA filing deadline.

The runway means Abivax does not need to tap capital markets urgently or rush a partnership. For a stock that has whipsawed hard in recent days, that liquidity also strengthens the company’s hand in any takeover negotiations – a scenario many investors had been betting on until safety questions emerged.

Powerful Efficacy Remains the Core Narrative

The Phase 3 ABTECT study, which enrolled 580 patients with ulcerative colitis, delivered a clear win on the primary endpoint at week 44. Both once-daily doses of Obefazimod produced remission rates far above placebo: 50.8% for the 25?mg arm and 51.3% for the 50?mg arm, against just 10.4% in the placebo group (p?<?0.0001). The placebo-adjusted figures of 39.3 and 40.3 percentage points underscore what analysts call a clinically relevant profile for a chronic inflammatory disease.

The strong data had made Abivax one of the most talked-about takeover targets in European biotech. But a series of malignancy cases reported in the study has given potential suitors pause, prompting the market to reassess the deal timeline.

Safety Signals Fuel Analyst Divergence

Prostate cancer, breast cancer and colon dysplasia each appeared once in the trial. At the higher 50?mg dose, four skin cancer cases were recorded: two were assessed as not or unlikely treatment-related, and the other two patients had prior skin cancer histories. The company said the independent reviewers did not attribute any of these events to therapy, nor did they see an organ-specific pattern.

While Stifel analyst Damien Choplain views the malignancy signal not as a proven safety risk but as a potential labeling overhang, the broader analyst community is unusually split.

• Citizens JMP stayed at Market Outperform and raised its price target to $187.
• Morgan Stanley maintained Overweight but cut to $132.
• Truist Securities reiterated Buy, trimming to $135.
• Jefferies downgraded from Buy to Hold and slashed to $90.
• Wedbush upgraded from Underperform to Neutral, also targeting $90.
• Wolfe Research kept Outperform but lowered to $136.

The average analyst target hovers near $130–147, and the consensus rating is a moderate buy. That range reflects a market still broadly positive on the drug’s prospects, but the gap between targets and the current share price – around €89–90 – shows how much trust Abivax must rebuild before October, when the full dataset is due.

Stock Volatility Captures the Uncertainty

Abivax shares jumped 17.97% on Thursday to close at €89.95, recouping some of the prior week’s losses. Even so, the stock remains down roughly 19–21% over seven days and 22% year?to?date. From its 52?week high of €130.80 set in January, the share price sits 31–32% lower. Yet the 12?month gain still stands at a remarkable 1,182%.

The trading pattern underscores how quickly sentiment has swung. The ABTECT data should have been an unalloyed positive, but the malignancy disclosures turned the narrative from straightforward efficacy win to a headache that could delay any takeover or complicate eventual FDA labeling. Jefferies, in its downgrade, cited an overhang that would be hard to shake.

Regulatory Path and Next Catalysts

Abivax is sticking with its original timeline. The New Drug Application for ulcerative colitis in the US is on track for late in the fourth quarter of 2026. Topline data from the Phase 2b induction study in Crohn’s disease are expected by mid?2027.

The company’s loss per share of $0.71 in the latest quarter beat the consensus estimate of $0.94, and quarterly revenue of $1.56?million came in well ahead of the $0.40?million forecast. For a development?stage biotech, however, clinical and regulatory milestones matter far more than quarterly turnover.

The real fork in the road arrives in October, when Abivax releases the complete safety dataset. If the independent reviewers’ assessment holds – that no causal link exists between Obefazimod and the cancer cases – the buyout buzz could return with force. If the overhang persists, the company may have to wait until it secures approval and a clear label to resolve the valuation discount. With nearly two years of cash in the bank, Abivax can afford to wait for the right answer.